# The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

> **NCT01189487** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 47 (actual)

## Conditions studied

- Pneumonia, Bacterial

## Interventions

- **DRUG:** ampicillin sodium/sulbactam sodium

## Key facts

- **NCT ID:** NCT01189487
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2012-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01189487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01189487, "The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01189487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*